Files in this item
Metformin and cardiorenal outcomes in diabetes : a reappraisal
Item metadata
dc.contributor.author | Petrie, John R | |
dc.contributor.author | Rossing, Peter R | |
dc.contributor.author | Campbell, Ian W | |
dc.date.accessioned | 2020-02-20T14:30:04Z | |
dc.date.available | 2020-02-20T14:30:04Z | |
dc.date.issued | 2020-02-18 | |
dc.identifier | 266393619 | |
dc.identifier | 7ec0a6db-6be1-43d9-82ea-13950c859348 | |
dc.identifier | 85079834299 | |
dc.identifier | 000529799300002 | |
dc.identifier.citation | Petrie , J R , Rossing , P R & Campbell , I W 2020 , ' Metformin and cardiorenal outcomes in diabetes : a reappraisal ' , Diabetes, Obesity and Metabolism , vol. Early View . https://doi.org/10.1111/dom.13984 | en |
dc.identifier.issn | 1462-8902 | |
dc.identifier.other | RIS: urn:283F4D5E02B8422004BFEE5492EB6B1E | |
dc.identifier.uri | https://hdl.handle.net/10023/19509 | |
dc.description.abstract | The guidance issued to the pharmaceutical industry by the US Food and Drug Administration in 2008 has led to the publication of a series of randomised, controlled cardiovascular outcomes trials with newer therapeutic classes of glucose‐lowering medications. Several of these trials, which evaluated the newer therapeutic classes of SGLT2 inhibitors and GLP‐1 receptor agonists have reported a reduced incidence of major adverse cardiovascular and/or renal outcomes, usually relative to placebo and standard of care. Metformin was the first glucose‐lowering agent reported to improve cardiovascular outcomes in the UK Prospective diabetes Study (UKPDS) and thus became the foundation of standard care. However, as this clinical trial reported more than 20 years ago, differences from current standards of trial design and evaluation complicate comparison of the cardiovascular profiles of older and newer agents. Our article revisits the evidence for cardiovascular protection with metformin and reviews its effects on the kidney. | |
dc.format.extent | 1408526 | |
dc.language.iso | eng | |
dc.relation.ispartof | Diabetes, Obesity and Metabolism | en |
dc.subject | Metformin | en |
dc.subject | Glucose-lowering therapy, atherosclerotic cardiovascular disease | en |
dc.subject | Chronic kidney disease | en |
dc.subject | Cardiovascular outcomes | en |
dc.subject | RA Public aspects of medicine | en |
dc.subject | SDG 3 - Good Health and Well-being | en |
dc.subject.lcc | RA | en |
dc.title | Metformin and cardiorenal outcomes in diabetes : a reappraisal | en |
dc.type | Journal item | en |
dc.contributor.institution | University of St Andrews. School of Medicine | en |
dc.identifier.doi | 10.1111/dom.13984 | |
dc.description.status | Peer reviewed | en |
dc.date.embargoedUntil | 2020-02-18 |
This item appears in the following Collection(s)
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.